2023-05-24 00:00:00來源:百奧利盟官方發(fā)布瀏覽量:169
2023年第26屆美國基因與細胞治療學(xué)會年會(ASGCT)的參會日程圓滿結(jié)束,百奧利盟作為全球精準醫(yī)療和創(chuàng)新生物藥數(shù)字化解決方案的服務(wù)商,聚焦細胞與基因治療數(shù)字化,發(fā)布Bio-CELL,Bio-LIMS,Bio-Research,Bio-Bank四個國際版數(shù)字化系統(tǒng),對布局深拓北美市場更加充滿信心!本次年會多家來自中國的企業(yè)充分彰顯中國力量,均在本屆大會展示其最新研究進展,涵蓋了基因編輯型TIL療法、基因替代療法、體內(nèi)RNA編輯療法等前沿療法,多項研究進行了口頭報告。
百奧利盟 BioTechLeague | Global Market
百奧利盟 BioTechLeague | Bio LIMS INC
Key Point: 百奧利盟?系統(tǒng)生態(tài)全覆蓋每個節(jié)點(Preclinical Testing, IND Application, Clinical Trials I II III, NDA Application, Approval),由研發(fā)到藥品申報直至商業(yè)化生產(chǎn)上市,百奧利盟系統(tǒng)(Bio-Research,Bio-Bank,Bio-COI,Bio-QCLIMS, Bio-CELL)均符合且支持藥企/醫(yī)院臨床中心發(fā)起申報上市路徑... ...
不管CAR-T、TILs還是CAR-NK全囊括強調(diào)了CoC及CoI基本追溯要求,數(shù)字化已然成為趨勢。CDE指南愈加細化并強調(diào)CoC及CoI基本追溯要求,其中《指南》強調(diào):企業(yè)應(yīng)當建立產(chǎn)品標識和追溯系統(tǒng),確保在供者材料運輸、接收以及產(chǎn)品生產(chǎn)和使用全過程中,來源于不同供者的產(chǎn)品不會發(fā)生混淆、差錯,確保供者材料或細胞與患者之間的匹配性,且可以追溯。
百奧利盟 BioTechLeague | Bio LIMS INC
Key Point:計算機化系統(tǒng)驗證CSV
根據(jù)ISPE GAMP5-2配合客戶完成計算機化系統(tǒng)驗證,可提供中英文驗證文件... ...
百奧利盟系統(tǒng)參考并遵守國際行業(yè)規(guī)范GAMP5和ALCOA+CCEA原則,以及NMPA《藥品記錄與數(shù)據(jù)管理要求(試行)》、《GMP附錄-細胞治療產(chǎn)品征求意見稿》相關(guān)法規(guī)和規(guī)范,支持細胞、基因治療企業(yè)臨床試驗、IND、NDA等計算機系統(tǒng)驗證CSV要求且提供雙語版功能,從而助力醫(yī)藥企業(yè)、科研機構(gòu)合規(guī)化生產(chǎn)管理,降低監(jiān)管難度,提供國際化接軌支持。
百奧利盟 BioTechLeague | Bio LIMS INC
Key Point: Bio-COI 系統(tǒng)用于身份鏈追溯,系統(tǒng)根據(jù)實際應(yīng)用場景設(shè)置有【醫(yī)院端】與【生產(chǎn)端】,支持在各個節(jié)點記錄信息并由對應(yīng)的人員確認,實現(xiàn)使用一個追溯碼就可以完成采樣到產(chǎn)品回輸?shù)娜鞒套匪?.. ...
細胞制備的唯一編碼貫穿于細胞全生命周期,從申請單錄入開始,經(jīng)歷來樣運輸、樣本接收、生產(chǎn)接收、生產(chǎn)計劃、生產(chǎn)、凍存、復(fù)蘇、傳代、外包環(huán)節(jié),經(jīng)過成品放行后最終完成細胞回輸,形成可雙向追溯的監(jiān)管鏈(COC)與身份鏈(COI)。在放行審核時可回顧細胞生產(chǎn)全過程,快速整理該訂單的質(zhì)控文檔與記錄,大大提高方形是對產(chǎn)品出場的質(zhì)量保證。細胞生產(chǎn)制備任務(wù)與質(zhì)檢任務(wù)雙向信息確認,對樣本進行質(zhì)控處理,異常樣本進入異常模塊,合格樣本流入下一步,質(zhì)量保證貫穿全程,產(chǎn)品檢測結(jié)束,出具產(chǎn)品檢驗報告單,進入工作流審批確認,對合格產(chǎn)品放行,對不合格產(chǎn)品出偏差報告。
Today: Watch the first oral abstract presentations, and hear from recipients of the Founders and Catalyst Awards.
ASGCT 26th Annual Meeting | Bio LIMS INC
Founders and Catalyst Award Lectures
3:45 - 5:30 p.m.
West Hall B
The Maturation of Hematopoietic Stem Cell Gene Therapy: Of Mice and Men
David A. Williams, MD
It's All About the Dose
Joy Cavagnaro, PhD
Today at the Annual Meeting: First day to visit the Exhibit Hall, attend the Outstanding Achievement Award and Presidential Symposia
ASGCT 26th Annual Meeting | Bio LIMS INC
Exhibit Hall Open
West Hall A
9:45 a.m. - 7 p.m.
Visit booths from 270 companies in the Exhibit Hall!
Outstanding Achievement Award Symposium
West Hall B
10:15 a.m. - 12 p.m.
J. Keith Joung, MD, PhD -?Gene Editing Voyages from Z to C (Zinc fingers to CRISPR)
Bruce L. Levine, PhD -?Translating T Cell Therapies From Boutique to Global (Inveniemus Aut Faciemus)
Isabelle Riviere, PhD -?Building a highway for CARs
Mark Dudley, PhD -?One Patient, One Product - The Development of Adoptive T-cell Therapy
Presidential Symposium + Presentation of Top Abstracts
West Hall B
1:30 - 3 p.m.
Jennifer Doudna, PhD -?CRISPR Chemistry and Applications in the Clinic
David R. Liu, PhD -?Base Editing and Prime Editing: Correction Mutations that Cause Genetic Disease in Cells, Animals, and Patients
We're also looking forward to more symposia and oral abstracts, the second day of the Career Fair, and the first-ever Women in Gene + Cell Therapy reception.
ASGCT 26th Annual Meeting | Bio LIMS INC
George Stamatoyannopoulos Memorial Lecture and Award Presentation
West Hall B
10:15 a.m.-12 p.m.
Stanley Riddell, MD -?Realizing the Potential of Genetically Engineered Immune Cells in Cancer Therapy
Crystal Mackall, MD -?Expanding the Reach and Efficacy of CAR T Cell Therapies
Grab an early breakfast with the Global Outreach Committee. Later, help us recognize our Outstanding New Investigator Award recipients!
ASGCT 26th Annual Meeting | Bio LIMS INC
This morning, finish up your time at the meeting with the final oral abstract sessions, symposia, & more!
ASGCT 26th Annual Meeting | Bio LIMS INC
來源:www.asgct.org